论文部分内容阅读
目的 观察缬沙坦对血液透析患者尿毒症心肌病的影响. 方法 将维持性血液透析合并尿毒症心肌病患者36例随机分为缬沙坦组19例及对照组17例,分别于透析治疗前、透析3个月后行心脏彩色多普勒检查,测量常规指标左室舒张末径(LVEDD)、收缩功能(EF)及舒张功能(E/A);同时于治疗前后测量血压(BP)、血肌酐( CRE)、甲状旁腺激素( iPTH)、红细胞( RBC)及血红蛋白( HGB). 结果 治疗前后2组患者CRE、iPTH、HGB、RBC水平均无显著性变化,差异无统计学意义( P>0.05). 治疗后缬沙坦组患者收缩压、舒张压均明显低于治疗前及对照组(P0.05). 对照组治疗前后LVEDD、EF及E/A均无明显改变,差异无统计学意义(P>0.05),而缬沙坦组治疗后LVEDD明显减小,EF明显升高,差异均有统计学意义(P0.05). 缬沙坦组与对照组治疗后比较,LVEDD及EF均有明显改变,差异有统计学意义( P0.05),and valsartan group after treatment,LVEDd decreased obviously,EF was significantly increased,the differences were statistically significant(P0.05).Valsartan group compared with the control group after treatment,LVEDD and EF were significantly changed,the difference was statistically significant(P<0.05). Conclusion Valsartan can reduce hemodialysis patients LVEDD ,elevating EF ,improving cardiac function .